Didanosine (ddI, Videx)

Overview | News | Research

Overview

Prescribing Information for Didanosine (ddI, Videx) (PDF) (November 2011)
From Bristol-Myers Squibb Company
Drug Interactions: Didanosine (August 2004)
From Project Inform

News

Safety Risk Associated With HIV Drug Videx (February 2, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Videx EC/Videx (Didanosine) Label Change Reflects Potential for Serious Liver Disorder (January 29, 2010)
From U.S. Food and Drug Administration
Important Changes to Videx (Didanosine) Labeling (June 19, 2009)
From U.S. Food and Drug Administration
Videx EC Labeling Changes With Pediatric Dosing Information Added (September 30, 2008)
From U.S. Food and Drug Administration
FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules (December 3, 2004)
From AIDSinfo
Thailand: Patients, Advocates Sue to Invalidate Videx EC Patent (October 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
New Safety Information for Videx (Didanosine, ddI) Used With Ribavirin (September 25, 2002)
From U.S. Food and Drug Administration
ddI-Tenofovir Interaction Warning (PDF) (May 7, 2002)
From Bristol-Myers Squibb Company
Drug Economy (July/August 2001)
Antiretroviral renegade fights fashion with didanosine + Hydroxyurea duo, betting his future on genetic barriers.
In TAGline, from Treatment Action Group
New Formulation of ddI Approved (March 2001)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
FDA Issues Warning About d4T and ddI During Pregnancy (January 22, 2001)
From Canadian AIDS Treatment Information Exchange

Research

Clinical Trials Using Didanosine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
ddI Resistance in South African Children Failing an Abacavir- or d4T-Based First-Line Regimen (March/April 2013)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here.
From D:A:D Steering Committee
Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO.com
ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
ddI + Tenofovir Combination Linked to Higher Pancreatitis Risk (October 2004)
Quick recap of a report in The Lancet.
In HIV Treatment ALERTS!, from The Center for AIDS
Micronutrient Supplement Can Improve d4T-, ddI-Related Neuropathy, Study Says (March/April 2004)
In Positively Aware, from Test Positive Aware Network

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	CROI 2013: Women's Issues in HIV Research (Video)
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.